Latest Commentary

Battle over generic-delaying continues

Yesterday, the congressional Subcommittee on Commerce, Trade, and Consumer Protection held a meeting to discuss Congressman Bobby Rush's (D-IL) new H.R.1706 bill--otherwise known as Protecting

Interphex Keynote: The changing landscape of biopharma

For the last week Steven Burrill has been on a mission. Talking to various media outlets, the noted venture capitalist has been sharing his view of what the future holds for the biotech and

Impressions from Interphex 2009

On Tuesday FiercePharma attended Interphex 2009 in New York City, where the sprawling Jacob Javitz center show floor (slideshow) was filled with the most cutting-edge biomanufacturing equipment the

FiercePharma on Twitter; at INTERPHEX 2009

I have three exciting items to share with FiercePharma readers today: Find us on Twitter - For all you Twitter users out there, you can now follow @FiercePharma, the new 140-character edition of our

Happy holidays!

With today's issue, we're concluding another year's coverage of the pharma industry. FiercePharma and its sister publications will be taking a publishing holiday until January 5th, when we'll be back

Multiple ways to get Fierce news!

Multiple ways to get Fierce news! Find yourself away from your email or simply overwhelmed by your inbox? FiercePharma now has a number of ways you can get the breaking Life Science industry news

FDA News in Review: September 2008

Today we're kicking off our first installment of "

Examining your relationship with CROs

Today we welcome another regular contributor to our Industry Voices column. Stephanie Wells is the Corporate Senior Vice President,

Publisher's Note: New mobile edition!

Publisher's Note: New mobile edition! We've been fielding a number of requests to make the newsletters easier to read, particularly on mobile devices. Today I'm pleased to announce the launch of our

Industry Voices

Today we introduce another name to our list of Industry Voices editors. Rhonda Greenapple is the president and founder of Reimbursement Intelligence, a consulting firm serving early stage biotech and